Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Supernus Pharmaceuticals ( (SUPN) ) has provided an announcement.
On February 18, 2026, Supernus Pharmaceuticals’ board approved Compensation Committee recommendations to raise base salaries and grant equity awards to its top executives, effective January 1, 2026, following an annual compensation review benchmarked to its industry peer group and advised by Aon. Chief executive Jack A. Khattar, chief financial officer Timothy C. Dec and other senior leaders received modest salary increases, 2025 cash bonuses, and new stock option, restricted stock unit and performance share unit grants, with equity awards vesting over four years or upon achievement of performance goals, underscoring the company’s continued emphasis on performance-based, equity-linked pay for key management.
The executive compensation changes tie a significant portion of leadership’s potential rewards to Supernus’s share price and the attainment of committee-approved operational or financial objectives. By keeping 2026 bonus targets unchanged while enhancing long-term incentive opportunities at a set exercise price, the board reinforces alignment between management and shareholder interests and signals confidence in the company’s future performance trajectory.
The most recent analyst rating on (SUPN) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.
Spark’s Take on SUPN Stock
According to Spark, TipRanks’ AI Analyst, SUPN is a Neutral.
Supernus Pharmaceuticals demonstrates strong product growth and a stable balance sheet, but faces profitability and cash flow challenges. The technical analysis suggests potential for recovery, while valuation metrics are currently unattractive. The earnings call provided a positive outlook, but highlighted operational losses and supply issues.
To see Spark’s full report on SUPN stock, click here.
More about Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments, primarily in neurology and psychiatry. The company operates in the U.S. specialty pharmaceuticals market, where it competes with peers on both innovative central nervous system therapies and lifecycle management of branded products.
Average Trading Volume: 668,907
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.88B
For detailed information about SUPN stock, go to TipRanks’ Stock Analysis page.